TY  - GEN
AU  - Carter,P
TI  - Improving the efficacy of antibody-based cancer therapies
SN  - 1474-175X
PY  - 2002///0416
KW  - Animals
KW  - Antibodies
KW  - immunology
KW  - Antibodies, Bispecific
KW  - therapeutic use
KW  - Antibodies, Monoclonal
KW  - Antibodies, Monoclonal, Humanized
KW  - Antibodies, Monoclonal, Murine-Derived
KW  - Antibodies, Neoplasm
KW  - Antibody-Dependent Cell Cytotoxicity
KW  - Antigens, Neoplasm
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Clinical Trials, Phase II as Topic
KW  - Clinical Trials, Phase III as Topic
KW  - Combined Modality Therapy
KW  - Cytokines
KW  - administration & dosage
KW  - Drug Delivery Systems
KW  - Humans
KW  - Immunization, Passive
KW  - Immunoconjugates
KW  - Immunotherapy
KW  - methods
KW  - Immunotoxins
KW  - Liposomes
KW  - Mice
KW  - Neoplasm Proteins
KW  - antagonists & inhibitors
KW  - Neoplasm, Residual
KW  - Neoplasms
KW  - drug therapy
KW  - Neovascularization, Pathologic
KW  - Prodrugs
KW  - Protein Engineering
KW  - Radioimmunotherapy
KW  - Recombinant Fusion Proteins
KW  - Rituximab
KW  - Trastuzumab
KW  - Treatment Outcome
KW  - Xenograft Model Antitumor Assays
N1  - Publication Type: Journal Article; Review
UR  - https://doi.org/10.1038/35101072
ER  -